Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 13/20 | 0.33 |
| ▸ | JAK1 | P23458 | 13/20 | 0.33 |
| ▸ | TYK2 | P29597 | 13/20 | 0.33 |
| ▸ | JAK3 | P52333 | 13/20 | 0.33 |
| ▸ | PLAT | P00750 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17604090 | 0.84 | RIPK2 (0.46) | ALOX15RIPK2TSHRLMNARAB9A | |
| SCHEMBL1164192 | 0.81 | RIPK2 (0.44) | ALOX15RIPK2TSHRLMNARAB9A | |
| SCHEMBL1717428 | 0.81 | RIPK2 (0.44) | ALOX15RIPK2TSHRLMNARAB9A | |
| SCHEMBL2078467 | 0.80 | RIPK2 (0.43) | ALOX15RIPK2TSHRLMNARAB9A | |
| SCHEMBL1717672 | 0.77 | RIPK2 (0.41) | ALOX15RIPK2TSHRLMNARAB9A | |
| SCHEMBL1717322 | 0.77 | JAK1 (0.41) | ALOX15RIPK2TSHRJAK2JAK1 | |
| SCHEMBL6346129 | 0.77 | RIPK2 (0.41) | ALOX15RIPK2TSHRLMNARAB9A | |
| SCHEMBL626803 | 0.75 | PARP1 (0.40) | ALOX15RIPK2TSHRJAK2JAK1 | |
| SCHEMBL6341305 | 0.72 | CNR2 (0.51) | RIPK2JAK2JAK1TYK2JAK3 | |
| SCHEMBL7883835 | 0.72 | TYK2 (0.41) | RIPK2TSHRJAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300478-B1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-9102679-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9096603-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140350025-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20140073641-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| EP-2414363-B1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2014-01-08 | — | — | EP | disclosed |
| US-8623901-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623879-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110082137-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| WO-2010112437-A1 | 1-HETEROCYCLYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | WO | disclosed |
| WO-2009121919-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | PDE9A, PDE7A, PDE1A | ALOX15 2009/4885RIPK2 3338/4885TSHR 3516/4885 |
| US-20140350025-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CHRM1, ATP6V1B2, CNR1 | ALOX15 1739/4885RIPK2 4654/4885TSHR 1921/4885 |
| US-20110082137-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CHRM1, CHRM2, CHRM5 | ALOX15 1604/4885RIPK2 4516/4885TSHR 1897/4885 |
| US-20140073641-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | PDE9A, PDE7A, PDE1A | ALOX15 4152/4885RIPK2 3482/4885TSHR 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.